Clinical Trials Browser

Terminated × INDUSTRY × Arsenic Trioxide × Clear all

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2 Terminated

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 2 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00513305 2012-08-01

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

Phase 3 Terminated

67 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia